Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenretinide intravenous - SciTech Development

Next Previous
Drug Profile

Fenretinide intravenous - SciTech Development

Alternative Names: fenretinide + lipids; nanoFenretinide drug delivery - SciTech Development; nanoFenretinide™; ST-001 - SciTech Development; ST-001 nanoFenretinide

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SciTech Development
  • Class Antifibrotics; Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Apoptosis stimulants; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I T-cell lymphoma
  • Preclinical Viral infections

Most Recent Events

  • 08 Apr 2025 SciTech Development plans a phase Ia/Ib trial for Small-cell lung cancer (Second-line theapy or greater) (IV, Infusion) in June 2025 (NCT06922539)
  • 08 Apr 2025 US FDA approves the IND application for a phase Ia/Ib trial in Small cell lung cancer
  • 04 Dec 2024 Preliminary efficacy and pharmacokinetics data from a phase I trial in T-cell lymphoma released by SciTech Development

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top